NEW YORK (GenomeWeb) ­– Quest Diagnostics has launched a new laboratory-developed assay to quantify hepatitis B surface antigen (HBsAg). Although quantitative HBsAg tests are widely used outside of the US, the test is the first to be offered stateside, potentially improving decision making for US physicians treating chronic HBV.

Hepatitis B virus infection, which affects up to 2.2 million people in the US, is typically detected and tracked in three ways: using viral DNA and two different viral surface proteins — HBsAg, and a surface protein called "e antigen," or HBeAg.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.